These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 18676135

  • 1. The effect of sibutramine therapy on occurrence of depression symptoms among obese patients.
    Slovacek L, Pavlik V, Slovackova B.
    Nutr Metab Cardiovasc Dis; 2008 Oct; 18(8):e43-4. PubMed ID: 18676135
    [No Abstract] [Full Text] [Related]

  • 2. Influence of weight reduction by sibutramine on female sexual function.
    Kim KK, Kang HC, Kim SS, Youn BB.
    Int J Obes (Lond); 2006 May; 30(5):758-63. PubMed ID: 16404407
    [Abstract] [Full Text] [Related]

  • 3. New obesity drug approved.
    Nurse Pract; 1998 Jan; 23(1):94, 99. PubMed ID: 9470201
    [No Abstract] [Full Text] [Related]

  • 4. Effect of sibutramine on weight reduction and insulin resistance in women with polycystic ovary syndrome.
    Georgopoulos NA, Katsikis I, Florakis D, Panidis D, Kandarakis ED.
    Fertil Steril; 2009 Jun; 91(6):e1. PubMed ID: 19362719
    [No Abstract] [Full Text] [Related]

  • 5. [Pharmacotherapy of obesity].
    Svendsen OL.
    Ugeskr Laeger; 2004 Oct 18; 166(43):3814-7. PubMed ID: 15544112
    [No Abstract] [Full Text] [Related]

  • 6. Sibutramine as an adjuvant therapy in adolescents suffering from morbid obesity.
    Reisler G, Tauber T, Afriat R, Bortnik O, Goldman M.
    Isr Med Assoc J; 2006 Jan 18; 8(1):30-2. PubMed ID: 16450748
    [Abstract] [Full Text] [Related]

  • 7. Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success.
    Elfhag K, Finer N, Rössner S.
    Diabetes Obes Metab; 2008 Jun 18; 10(6):498-505. PubMed ID: 17593239
    [Abstract] [Full Text] [Related]

  • 8. Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 gene.
    Hsiao DJ, Wu LS, Huang SY, Lin E.
    Pharmacogenet Genomics; 2009 Sep 18; 19(9):730-3. PubMed ID: 19687782
    [Abstract] [Full Text] [Related]

  • 9. Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study.
    Kiortsis DN, Tsouli S, Filippatos TD, Konitsiotis S, Elisaf MS.
    Nutr Metab Cardiovasc Dis; 2008 Mar 18; 18(3):207-10. PubMed ID: 17570651
    [Abstract] [Full Text] [Related]

  • 10. [Back at the starting point. Obesity patients the losers when sibutramine (Reductil) is recalled].
    Rössner S.
    Lakartidningen; 2008 Mar 18; 107(5):269. PubMed ID: 20297569
    [No Abstract] [Full Text] [Related]

  • 11. Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients.
    Early JL, Apovian CM, Aronne LJ, Fernstrom MH, Frank A, Greenway FL, Heber D, Kushner RF, Cwik KM, Walch JK, Hewkin AC, Blakesley V.
    Obesity (Silver Spring); 2007 Jun 18; 15(6):1464-72. PubMed ID: 17557984
    [Abstract] [Full Text] [Related]

  • 12. Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study.
    Di Francesco V, Sacco T, Zamboni M, Bissoli L, Zoico E, Mazzali G, Minniti A, Salanitri T, Cancelli F, Bosello O.
    Ann Nutr Metab; 2007 Jun 18; 51(1):75-81. PubMed ID: 17356258
    [Abstract] [Full Text] [Related]

  • 13. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients.
    Finer N, Ryan DH, Renz CL, Hewkin AC.
    Diabetes Obes Metab; 2006 Mar 18; 8(2):206-13. PubMed ID: 16448525
    [Abstract] [Full Text] [Related]

  • 14. Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine.
    Vazquez Roque MI, Camilleri M, Clark MM, Tepoel DA, Jensen MD, Graszer KM, Kalsy SA, Burton DD, Baxter KL, Zinsmeister AR.
    Clin Gastroenterol Hepatol; 2007 Jul 18; 5(7):829-37. PubMed ID: 17544870
    [Abstract] [Full Text] [Related]

  • 15. Long-term medication use and weight loss maintenance: an observational study.
    Womble LG, Wadden TA, Berkowitz RI, Sarwer DB, Rothman RA.
    Obes Res; 2001 Oct 18; 9(10):652-3. PubMed ID: 11595785
    [No Abstract] [Full Text] [Related]

  • 16. Sibutramine in cardiovascular disease: is SCOUT the new STORM on the horizon?
    von Haehling S, Lainscak M, Anker SD.
    Eur Heart J; 2007 Dec 18; 28(23):2830-1. PubMed ID: 17984134
    [No Abstract] [Full Text] [Related]

  • 17. [Patients with type III obesity given sibutramine 15 mg/day lose weight in amounts proportional to those in types I and II, but waist circumferences does not decrease proportionally].
    López-Alvarenga JC, Vargas JA, Schneider-Ehrenberg OP, Comuzzie AG, González J, Martínez JL.
    Gac Med Mex; 2007 Dec 18; 143(2):109-14. PubMed ID: 17585697
    [Abstract] [Full Text] [Related]

  • 18. An obesity drug sibutramine reduces brain natriuretic peptide (BNP) levels in severely obese patients.
    Taner Ertugrul D, Yavuz B, Okhan Akin K, Arif Yalcin A, Ata N, Kucukazman M, Algul B, Dal K, Sinan Deveci O, Tutal E.
    Int J Clin Pract; 2010 Mar 18; 64(4):518-22. PubMed ID: 20456197
    [Abstract] [Full Text] [Related]

  • 19. [Struggle about the best reducing diet, Fat gone by means of more fat?].
    Bischoff A.
    MMW Fortschr Med; 2004 Jan 15; 146(1-2):4-6. PubMed ID: 18441569
    [No Abstract] [Full Text] [Related]

  • 20. Effect of sibutramine and of cognitive-behavioural weight loss therapy in obesity and subclinical binge eating disorder.
    Bauer C, Fischer A, Keller U.
    Diabetes Obes Metab; 2006 May 15; 8(3):289-95. PubMed ID: 16634988
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.